Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer.
Cole relaxation frequency
bioelectrical impedance
breast cancer
prognosis
recurrence
Journal
Journal of patient-centered research and reviews
ISSN: 2330-0698
Titre abrégé: J Patient Cent Res Rev
Pays: United States
ID NLM: 101646624
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
epublish
Résumé
We previously reported successful classification of breast cancer versus benign tissue using the Cole relaxation frequency measured on tissue excised during breast surgery as part of a study at two urban hospitals in the U.S. Midwest. Using that health system's cancer registry, we have discovered retrospectively that outcomes for patients who participated in the initial study can be classified correctly in 3 well-differentiated categories: nonrecurrent (NR); recurrent with no metastasis (RNM); and recurrent with metastasis (RM). As Cole relaxation frequency increases, the classification moves from NR to RNM and finally to RM. Multivariate analysis showed a significant association of "time-cancer-free" for all patients in these recurrent categories, with P-values ranging between 0.0001 to 0.0047. Thus, this follow-up report shows the potential feasibility of using Cole relaxation frequency as a prognostic parameter in a larger prospective study.
Identifiants
pubmed: 33163555
doi: 10.17294/2330-0698.1794
pii: jpcrr-7.4.343
pmc: PMC7644131
doi:
Types de publication
Journal Article
Langues
eng
Pagination
343-348Subventions
Organisme : NCI NIH HHS
ID : P30 CA138313
Pays : United States
Informations de copyright
© 2020 Aurora Health Care, Inc.
Déclaration de conflit d'intérêts
Conflicts of Interest William Gregory and Shahila Mehboob Christie are employed at NovaScan, Inc., and Gregory and John Shell are stockholders in the company. NovaScan has patents pending on technology related to the research reported here. Advocate Aurora Health is a stockholder in NovaScan, but Wendy Mikkelson has no financial interest in the company. The remaining authors (Maharaj Singh and Georges Nahhas) have no conflicts of interest to report.
Références
Breast Cancer (Dove Med Press). 2017 May 29;9:393-400
pubmed: 28615971
J Pathol Clin Res. 2016 Jan 15;2(1):32-40
pubmed: 27499914
Br J Cancer. 1982 Mar;45(3):361-6
pubmed: 7073932
IEEE J Transl Eng Health Med. 2017 Nov 15;5:2800607
pubmed: 29282435
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Med Phys. 2012 Jul;39(7):4167-74
pubmed: 22830750
Cancer Cell Int. 2007 Mar 15;7:2
pubmed: 17362521
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
Cancer Res. 2009 Jul 1;69(13):5357-63
pubmed: 19549915
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201
pubmed: 26867046
J Am Acad Dermatol. 2018 Sep;79(3):591-593
pubmed: 29544743
Breast Cancer Res Treat. 2016 May;157(1):65-75
pubmed: 27116185